Mylan Specialty

CompanyUnited States

Mylan Specialty develops one asset, in phase 2, discontinued (silibinin in amanita poisoning). Mostly small molecule; based in the United States.

1
Asset
Furthest stage
Phase 2, discontinued
1
Trial
4
Signals

Pipeline

1
  • silibinin

    Inhibits hepatitis C virus replication and entry into liver cells.

    Phase 2, discontinued, Small molecule, amanita poisoning, amatoxin poisoning

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials3
  • Signals6
  • Similar companies6

Intelligence